Toll Free: 1-888-928-9744
Published: Sep, 2014 | Pages:
35 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
ContraFect Corporation - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'ContraFect Corporation - Product Pipeline Review - 2014', provides an overview of the ContraFect Corporation's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of ContraFect Corporation's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of ContraFect Corporation including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of ContraFect Corporation's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the ContraFect Corporation's pipeline products Reasons to buy - Evaluate ContraFect Corporation's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of ContraFect Corporation in its therapy areas of focus - Identify new drug targets and therapeutic classes in the ContraFect Corporation's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of ContraFect Corporation and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of ContraFect Corporation - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of ContraFect Corporation and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 ContraFect Corporation Snapshot 5 ContraFect Corporation Overview 5 Key Information 5 Key Facts 5 ContraFect Corporation - Research and Development Overview 6 Key Therapeutic Areas 6 ContraFect Corporation - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 ContraFect Corporation - Pipeline Products Glance 11 ContraFect Corporation - Early Stage Pipeline Products 11 Preclinical Products/Combination Treatment Modalities 11 Discovery Products/Combination Treatment Modalities 12 ContraFect Corporation - Drug Profiles 13 CF-301 13 Product Description 13 Mechanism of Action 13 R&D Progress 13 CF-401 14 Product Description 14 Mechanism of Action 14 R&D Progress 14 CF-402 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 CF-403 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 CF-404 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 Monoclonal Antibody 1 for Influenza 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 CF-302 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 CF-303 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 CF-304 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 CF-305 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 CF-306 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 CF-307 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 CF-308 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 CF-309 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 Monoclonal Antibodies for Influenza 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 ContraFect Corporation - Pipeline Analysis 28 ContraFect Corporation - Pipeline Products by Target 28 ContraFect Corporation - Pipeline Products by Molecule Type 29 ContraFect Corporation - Pipeline Products by Mechanism of Action 30 ContraFect Corporation - Recent Pipeline Updates 31 ContraFect Corporation - Dormant Projects 32 ContraFect Corporation - Locations And Subsidiaries 33 Head Office 33 Appendix 34 Methodology 34 Coverage 34 Secondary Research 34 Primary Research 34 Expert Panel Validation 34 Contact Us 35 Disclaimer 35
List of Tables ContraFect Corporation, Key Information 5 ContraFect Corporation, Key Facts 5 ContraFect Corporation - Pipeline by Indication, 2014 8 ContraFect Corporation - Pipeline by Stage of Development, 2014 9 ContraFect Corporation - Monotherapy Products in Pipeline, 2014 10 ContraFect Corporation - Preclinical, 2014 11 ContraFect Corporation - Discovery, 2014 12 ContraFect Corporation - Pipeline by Target, 2014 28 ContraFect Corporation - Pipeline by Molecule Type, 2014 29 ContraFect Corporation - Pipeline Products by Mechanism of Action, 2014 30 ContraFect Corporation - Recent Pipeline Updates, 2014 31 ContraFect Corporation - Dormant Developmental Projects,2014 32
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.